Biopharmaceutical manufacturer BioMarin is giving 340B covered entities refunds for overcharges on five of its six approved medicines from Q1 2019 through Q4 2020.
The California-based company posted a notice about the availability of the refunds last week on the U.S. Health Resources and Services Administration (HRSA) website. The notice said BioMarin recalculated its 340B ceiling prices for the two-year period, but it did not state the reason why the company did so.
Biopharmaceutical manufacturer BioMarin is giving 340B covered entities refunds for overcharges on five of its six approved medicines from Q1 2019 through Q4 2020.
Please Login or Become a Paid Subscriber to View this Content
If you are already a paid subscriber, please follow the steps below.
